JETEMA's Botulinum Toxin JTM201 Succeeds in China Phase 3 Trial: Non-inferiority to Botox Demonstrated, Green Light for China Market Entry
JETEMA disclosed on May 28, 2026, the results of the first stage of its Phase 3 clinical trial in China for its botulinum toxin product JTM201 (JETEMA Toxin 100 Units).
The trial was a multicenter, randomized, double-blind, non-inferiority, active-controlled study comparing JTM201 with Botox® for the improvement of moderate-to-severe glabellar lines, enrolling a total of 506 subjects (253 per arm).
Key results: At 4 weeks post-injection, JTM201 demonstrated non-inferiority to Botox in glabellar line improvement rates, and efficacy was similar up to 16 weeks. Safety profiles were comparable, with no drug-related serious adverse events or discontinuations.
Based on these results, JETEMA plans to submit a marketing authorization application to the National Medical Products Administration (NMPA) in China and will continue development for global market entry and label expansion.
[AI Comprehensive Analysis]This successful Phase 3 outcome significantly increases the likelihood of JTM201's approval in China, potentially triggering a revaluation of the company. However, final regulatory approval remains uncertain, and commercialization risks such as intense competition and pricing pressure should be considered.
KOSDAQ Filing Information
Filing: Material Management Matters Related To Investment Decision (Clinical Trial Results) (JETEMA DERTUSIN Injection 100 Units (JTM201) Phase 3, Stage 1 Results In China)